Production and Preparation

PP-041

CENTRALISED NON-HAZARDOUS INTRAVENOUS COMPOUNDING: FROM THEORY TO CLINICAL PRACTICE

PP-057

PHARMACEUTICAL QUALIFICATION OF BIOINVERT® 200, AN ENZYME SUBSTITUTE TO SUCRAID®

PP-021

EVALUATION OF THE SURFACE CONTAMINATION IN A CHEMOTHERAPY PREPARATION UNIT BEFORE A PROCESS CHANGE

PP-012

 CONSERVING COLD CHAIN COMPLIANCE IN THE RECONSTITUTION OF VIDAZA® IN ISOLATORS 

PP-058

EVOLUTION OF THE PAEDIATRIC PARENTERAL NUTRITION BAG PRESCRIPTIONS FURTHER TO THE NUMETAH (THREE CHAMBER BAG) MARKETING

PP-054

STABILITY STUDY OF 100 MG/ML PAEDIATRIC PYRAZINAMIDE ORAL SUSPENSION IN SYRSPEND

PP-051

CYTOTOXIC CONTAMINATION RESEARCH IN A CENTRALISED CYTOTOXIC UNIT TO IMPROVE PROFESSIONAL PRACTICES

PP-049

IMPACT OF IMMUNOTHERAPY ARRIVAL IN CHEMOTHERAPY PRODUCTION UNITS : RETROSPECTIVE STUDY AND PROJECTION WITH ANTI-PD-1 AGENTS

PP-048

ANTINEOPLASIC: ANTICIPATED PREPARATIONS OR LONGER OPENING HOURS?

PP-047

AUTOMATED INTRAVENOUS CHEMOTHERAPY WORKFLOW: THE ADDED BENEFIT TO REDUCE POTENTIAL MEDICATION ERRORS

PP-046

A STABILITY INDICATING HPLC-UV METHOD FOR QUANTIFICATION OF SIMVASTATIN AND DETECTION OF ITS IMPURITIES IN ORAL CAPSULES

PP-044

STABILITY OF 50 AND 100μG/0.1ML INTRAOCULAR SOLUTIONS OF VORICONAZOLE AT 2-8°C

PP-041

CENTRALISED NON-HAZARDOUS INTRAVENOUS COMPOUNDING: FROM THEORY TO CLINICAL PRACTICE

PP-040

EVALUATION OF THERAPY MANAGEMENT FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING IN A CENTRALISED INTRAVENOUS COMPOUNDING FACILITY

PP-039

IMPACT OF MASKING OF METHYLPHENIDATE DISSOLUTION FOR OVER ENCAPSULATED CAPSULES OF RITALIN LA 10 MG

Pages